# Alastair J Hutchison

## List of Publications by Citations



| 72 | 2,466 | 30 | 49 |
|---|---|---|---|
| papers | citations | h-index | g-index |
| 76 | 2,679 | 4.6 | 4.69 |
| ext. papers | ext. citations | avg, IF | L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 72 | A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. *Kidney International*, **2003**, S73-8 | 9.9 | 237 |
| 71 | Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. *Kidney International*, **1993**, 44, 1071-7 | 9.9 | 168 |
| 70 | Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. *Kidney International*, **2005**, 68, 2381-8 | 9.9 | 117 |
| 69 | Bone loss in long-term renal transplantation: histopathology and densitometry analysis. *Kidney International*, **1999**, 55, 2021-9 | 9.9 | 105 |
| 68 | Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. *Kidney International*, **2000**, 58, 1440-9 | 9.9 | 97 |
| 67 | Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. *Nephron Clinical Practice*, **2008**, 110, c15-23 | | 90 |
| 66 | Oral phosphate binders. *Kidney International*, **2009**, 75, 906-14 | 9.9 | 81 |
| 65 | Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. *Nephron Clinical Practice*, **2006**, 102, c61-71 | | 79 |
| 64 | Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. *American Journal of Kidney Diseases*, **2000**, 35, 227-36 | 7.4 | 76 |
| 63 | Pharmacology, efficacy and safety of oral phosphate binders. *Nature Reviews Nephrology*, **2011**, 7, 578-89 | 14.9 | 70 |
| 62 | Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. *Nephrology Dialysis Transplantation*, **1992**, 7, 1219-25 | 4.3 | 69 |
| 61 | Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. *Nephrology Dialysis Transplantation*, **2004**, 19, 1902-6 | 4.3 | 64 |
| 60 | Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. *Nephrology Dialysis Transplantation*, **1996**, 11, 2430-8 | 4.3 | 59 |
| 59 | Cardiovascular disease in patients with chronic kidney disease. *Vascular Health and Risk Management*, **2009**, 5, 713-22 | 4.4 | 58 |
| 58 | Proximal calciphylaxis treated with calcimimetic ŤCinacalcetŤ *Nephrology Dialysis Transplantation*, **2008**, 23, 387-9 | 4.3 | 56 |
| 57 | Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. *International Journal of Clinical Practice*, **2005**, 59, 1091-6 | 2.9 | 56 |
| 56 | Hyperphosphataemia in renal failure: causes, consequences and current management. *Drugs*, **2003**, 63, 577-96 | 12.1 | 55 |

| | | | |
|---|---|---|---|
| 55 | Histological, radiological, and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis patients. *American Journal of Nephrology*, **1994**, 14, 19-29 | 4.6 | 53 |
| 54 | Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. *Nephrology Dialysis Transplantation*, **2005**, 20, 775-82 | 4.3 | 47 |
| 53 | Incidence and consequence of acute kidney injury in unselected emergency admissions to a large acute UK hospital trust. *BMC Nephrology*, **2014**, 15, 84 | 2.7 | 46 |
| 52 | Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. *Nephrology Dialysis Transplantation*, **2008**, 23, 3677-84 | 4.3 | 46 |
| 51 | Bone histopathology and densitometry comparison between cyclosporine a monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients. *Transplantation*, **2003**, 75, 2053-8 | 1.8 | 45 |
| 50 | Risk factors for non-ischaemic foot ulceration in diabetic nephropathy. *Diabetic Medicine*, **1991**, 8, 223-5 | 3.5 | 45 |
| 49 | Peritoneal tuberculosis in patients receiving continuous ambulatory peritoneal dialysis. *Nephrology Dialysis Transplantation*, **2001**, 16, 1024-7 | 4.3 | 42 |
| 48 | Lanthanum carbonate: safety data after 10 years. *Nephrology*, **2016**, 21, 987-994 | 2.2 | 41 |
| 47 | Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients. *Expert Opinion on Pharmacotherapy*, **2005**, 6, 319-28 | 4 | 40 |
| 46 | Severe acute renal failure in adults: place of care, incidence and outcomes. *QJM - Monthly Journal of the Association of Physicians*, **2005**, 98, 661-6 | 2.7 | 36 |
| 45 | Improving phosphate-binder therapy as a way forward. *Nephrology Dialysis Transplantation*, **2004**, 19 Suppl 1, i19-24 | 4.3 | 36 |
| 44 | Calcium and Magnesium Mass Transfer in Peritoneal Dialysis Patients Using 1.25 Mmol/L Calcium, 0.25 Mmol/L Magnesium Dialysis Fluid. *Peritoneal Dialysis International*, **1993**, 13, 219-223 | 2.8 | 35 |
| 43 | Nutritional Management of Patients Undergoing Surgery following Diagnosis with Encapsulating Peritoneal Sclerosis. *Peritoneal Dialysis International*, **2008**, 28, 271-276 | 2.8 | 31 |
| 42 | Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients. *Clinical Journal of the American Society of Nephrology: CJASN*, **2009**, 4, 401-9 | 6.9 | 30 |
| 41 | Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations. *Nephron*, **1996**, 72, 52-8 | 3.3 | 25 |
| 40 | Outcomes of peritoneal dialysis patients and switching to hemodialysis: a competing risks analysis. *Peritoneal Dialysis International*, **2014**, 34, 289-98 | 2.8 | 24 |
| 39 | A Multifaceted Quality Improvement Programme to Improve Acute Kidney Injury Care and Outcomes in a Large Teaching Hospital. *BMJ Quality Improvement Reports*, **2017**, 6, | | 23 |
| 38 | Side-effects of antituberculosis drug treatment in patients with chronic renal failure. *European Respiratory Journal*, **2002**, 20, 440-3 | 13.6 | 23 |

| | | | |
|---|---|---|---|
| 37 | Decrease in infections with the introduction of mupirocin cream at the peritoneal dialysis catheter exit site. *Journal of Nephrology*, **2004**, 17, 242-5 | 4.8 | 22 |
| 36 | Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate. *Therapeutics and Clinical Risk Management*, **2008**, 4, 887-93 | 2.9 | 18 |
| 35 | Quality of life in CAPD, transplant, and chronic renal failure patients with diabetes. *Renal Failure*, **2007**, 29, 189-97 | 2.9 | 15 |
| 34 | Increased mortality due to cardiovascular disease in type 1 diabetic patients transplanted for end-stage renal failure. *Diabetic Medicine*, **1994**, 11, 987-91 | 3.5 | 15 |
| 33 | Profiling patient attitudes to phosphate binding medication: a route to personalising treatment and adherence support. *Psychology and Health*, **2014**, 29, 1407-20 | 2.9 | 14 |
| 32 | Use of magnesium as a drug in chronic kidney disease. *CKJ: Clinical Kidney Journal*, **2012**, 5, i62-i70 | 4.5 | 13 |
| 31 | Dialysis therapies for end-stage renal disease. *Seminars in Dialysis*, **2002**, 15, 220-6 | 2.5 | 13 |
| 30 | Oral phosphate binders for the management of serum phosphate levels in dialysis patients. *Journal of Renal Care*, **2009**, 35 Suppl 1, 65-70 | 1.6 | 12 |
| 29 | Association of sex hormone status with the bone loss of renal transplant patients. *Nephrology Dialysis Transplantation*, **2001**, 16, 1245-50 | 4.3 | 12 |
| 28 | Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis. *Peritoneal Dialysis International*, **2008**, 28, 271-6 | 2.8 | 12 |
| 27 | Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients. *BMC Nephrology*, **2013**, 14, 40 | 2.7 | 11 |
| 26 | Lanthanum carbonate--a first line phosphate binder?. *Seminars in Dialysis*, **2007**, 20, 325-8 | 2.5 | 10 |
| 25 | Acute arteriovenous access failure: long-term outcomes of endovascular salvage and assessment of co-variates affecting patency. *Nephron*, **2015**, 129, 241-6 | 3.3 | 9 |
| 24 | Update and critical appraisal of sevelamer in the management of chronic renal failure. *Open Access Journal of Urology*, **2010**, 2, 161-70 | | 9 |
| 23 | Calcium and Magnesium Flux in Automated Peritoneal Dialysis. *Peritoneal Dialysis International*, **2009**, 29, 536-541 | 2.8 | 9 |
| 22 | Low Turnover Bone Disease. *Peritoneal Dialysis International*, **1996**, 16, 295-299 | 2.8 | 9 |
| 21 | A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis. *BMC Nephrology*, **2019**, 20, 37 | 2.7 | 8 |
| 20 | Long-Term Mortality and Bone Safety in Patients with End-Stage Renal Disease Receiving Lanthanum Carbonate. *Nephron*, **2018**, 140, 265-274 | 3.3 | 8 |

| | | | |
|---|---|---|---|
| 19 | Variability in parathyroid hormone assays confounds clinical practice in chronic kidney disease patients. *Annals of Clinical Biochemistry*, **2014**, 51, 228-36 | 2.2 | 7 |
| 18 | Novel phosphate binders: plus ã change, plus c'est la mẽme chose. *Kidney International*, **2014**, 86, 471-4 | 9.9 | 6 |
| 17 | Predialysis management of divalent ion metabolism. *Kidney International*, **1999**, 73, S82-4 | 9.9 | 5 |
| 16 | Calcium and magnesium flux in automated peritoneal dialysis. *Peritoneal Dialysis International*, **2009**, 29, 536-41 | 2.8 | 5 |
| 15 | A Study to Inform the Design of a National Multicentre Randomised Controlled Trial to Evaluate If Reducing Serum Phosphate to Normal Levels Improves Clinical Outcomes including Mortality, Cardiovascular Events, Bone Pain, or Fracture in Patients on Dialysis. *International Journal of Nephrology*, **2015**, 2015, 579434 | 1.7 | 4 |
| 14 | Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed?. *Seminars in Dialysis*, **2007**, 20, 24-32 | 2.5 | 3 |
| 13 | Hyperphosphataemia in 2019: have we made progress?. *Current Opinion in Nephrology and Hypertension*, **2019**, 28, 441-447 | 3.5 | 3 |
| 12 | Lanthanum and phosphate: science, policy, and survival. *Kidney International*, **2009**, 75, 355-7 | 9.9 | 2 |
| 11 | Enabling self-management: selecting patients for home dialysis?. *CKJ: Clinical Kidney Journal*, **2011**, 4, iii7-iii10 | 4.5 | 2 |
| 10 | Reducing dialysate calcium - a reasonable strategy?. *Nephron Clinical Practice*, **2004**, 96, c1-2 | | 2 |
| 9 | Encapsulating peritoneal sclerosis following renal transplantation despite tamoxifen and immunosuppressive therapy. *CKJ: Clinical Kidney Journal*, **2008**, 1, 333-5 | 4.5 | 1 |
| 8 | Recurrent Escherichia coli bacteraemia in a patient with chronic renal failure. *Nephrology Dialysis Transplantation*, **2001**, 16, 2429-30 | 4.3 | 1 |
| 7 | Calcium, phosphate and renal osteodystrophy **1994**, 529-553 | | 1 |
| 6 | Peritoneal Dialysis Solutions **2017**, 408-417.e1 | | 0 |
| 5 | Prescribing high-quality peritoneal dialysis: Moving beyond urea clearance. *Peritoneal Dialysis International*, **2020**, 40, 293-301 | 2.8 | |
| 4 | Lanthanum carbonate for hyperphosphatemia in patients with advanced CKD and patients receiving dialysis. *Expert Review of Endocrinology and Metabolism*, **2009**, 4, 307-316 | 4.1 | |
| 3 | Peritoneal Dialysis Solutions **2008**, 558-568 | | |
| 2 | Opinion: Which of the K/DOQI Guidelines for Bone Disease in Dialysis Patients Should be Changed?. *Seminars in Dialysis*, **2007**, 20, 26-28 | 2.5 | |

1 Dialysate calcium and calcium/phosphate balance in hemodialysis. *Hemodialysis International*, **2007**, 11, S27-S33 1.7